Opus Medical Therapies

Castle Placement tracks the top 10 capital raises in U.S. healthcare devices and supplies for September 2026. The report highlights funding rounds and investor participation in the sector. Specific companies, raise amounts, or investor names are not detailed in the provided text.

Oct 2026Castle Placement®News article

Venus Medtech partners with Opus Medical Therapies to develop, manufacture, and market **transcatheter mitral valve replacement (TMVR)** and **transcatheter tricuspid valve replacement (TTVR)** products in China. The collaboration expands access to advanced cardiac interventions in the region. Both companies specialize in structural heart disease solutions.

May 2020NS Medical DevicesNews article

Venus Medtech and Opus Medical Therapies, LLC have formed a partnership to advance **transcatheter mitral valve replacement (TMVR)** and **transcatheter tricuspid valve replacement (TTVR)** in the **Greater China market**. The collaboration aims to expand access to minimally invasive cardiac treatments for patients with mitral and tricuspid valve disorders. Both companies specialize in structural heart disease interventions, combining Venus Medtech’s regional expertise with Opus Medical’s proprietary valve technologies.

May 2020PR NewswireNews article

Venus Medtech and Opus Medical Therapies collaborate to develop transcatheter valve technology targeting the Greater China market. Venus Medtech, a Chinese company specializing in transcatheter heart valves, joins forces with Opus Medical Therapies, an Atlanta-based medical device firm. The partnership aims to advance cardiac intervention solutions for patients in the region.

May 2020Cardiac Interventions TodayNews article